Vixarelimab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Vixarelimab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Phase 1/2
Highest phase
5
Registered trials
5
Result records
1
Matched deals
Executive recommendation: CONDITIONAL GO
Decision memo
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
The central underwriting question is whether Vixarelimab can convert its Monoclonal antibody profile and IL-31RB biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Vixarelimab (query alias: vixarelimab) |
|---|---|
| Modality / target | Monoclonal antibody; IL-31RB; OSMRβ inhibitors |
| Highest global status | Phase 1/2 |
| Originator | Biogen, Inc. |
| Active developers | Genentech, Inc. |
The MCP disease footprint includes Colitis, Ulcerative. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT05785624 | Phase 2 | Terminated | 286 | Cohorts 1 and 2: Absolute Change From Baseline in Forced Vital Capacity (FVC) |
| NCT06137183 | Phase 2 | 主动终止 | 79 | Percentage of Participants With Clinical Remission at Week 12 |
| NCT03858634 | Phase 2 | Completed | 58 | Change From Baseline in Weekly Average WI-NRS at Week 8 |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A Phase II, Multicenter Induction Study With an Active Treatment Extension to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Patients With Moderate to Severe Ulcerative Colitis
Phase 2; n=79; evaluation: not stated. Reported fields: Percentage of Participants With Clinical Remission at Week 12 = 3.8 percentage of participants (95% Confidence Interval, 0.68 - 18.89); Percentage of Participants With Clinical Remission at Week 12: Adjusted Difference in Remission Rates = 0.0(95% CI, -17.11 to 17.11), P-Value = 1.0000; Adjusted Difference in Remission Rates = -7.7(95% CI, -21.94 to 6.47), P-Value = 0.3010; Percentage of Participants With Clinical Remission at Week 12 = 11.5 percentage of participants (95% Confidence Interval, 4.00 - 28.98)
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritus in Subjects With Prurigo Nodularis
Phase 2; n=240; evaluation: not stated. Reported fields: Phase 2a & 2b: Percent Change From Baseline in Weekly Average Worst Itch-Numeric Rating Scale (WI-NRS) Score(Least Squares Mean) = -51.0 percentage change (Standard Error, 4.83); Phase 2a & 2b: Percent Change From Baseline in Weekly Average Worst Itch-Numeric Rating Scale (WI-NRS) Score(Least Squares Mean): LS Mean Difference = -21.2(95% CI, -40.82 to -1.60), P-Value = 0.0347; LS Mean Difference = -41.7(95% CI, -54.9 to -28.5), P-Value = <0.0001; LS Mean Difference = -36.4(95% CI, -49.6 to 23.3), P-Value = <0.0001; LS Mean Difference = -18.4(95% CI, -31.6 to -5.3), P-Value = 0.0061; Phase 2a & 2b: Percent Change From Baseline in Weekly Average Worst Itch-Numeric Rating Scale (WI-NRS) Score(Least Squares Mean): LS Mean Difference = -21.2(95% CI, -40.82 to -1.60), P-Value = 0.0347; LS Mean Difference = -41.7(95% CI, -54.9 to -28.5), P-Value = <0.0001; LS Mean Difference = -36.4(95% CI, -49.6 to 23.3), P-Value = <0.0001; LS Mean Difference = -18.4(95% CI, -31.6 to -5.3), P-Value = 0.0061
Vixarelimab in Patients With Prurigo Nodularis
Phase 2; n=190; evaluation: Positive. Reported fields: PN Investigator Global Assessment(16 week) = 10.4 % ; PN Investigator Global Assessment(16 week) = 29.8 % ; PN Investigator Global Assessment(16 week) = 38.3 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Vixarelimab addresses Colitis, Ulcerative. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2022-08-02 | Genentech and Roche will collaborate with Kiniksa to globally develop and market vixarelimab for the treatment of autoinflammatory diseases. | Phase 2 | US$100.0M upfront; US$600.0M milestones; US$700.0M stated total |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
CONDITIONAL GO
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
